IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding IN8BIO, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 12 | 19 | +7 |
| Shares | 875.5K | 980.3K | +104.8K (+12.0%) |
| Value | $1.83M | $2.13M | +$297.5K (+16.3%) |
New holders (8)
Institutions that held IN8BIO, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Investments, LP | 49,453 | $107.3K | 0.00% |
| Two Sigma Advisers, LP | 45,751 | $99.3K | 0.00% |
| Jane Street Group, LLC | 26,182 | $56.8K | 0.00% |
| Citadel Advisors LLC | 24,728 | $53.7K | 0.00% |
| DRW Securities, LLC | 18,300 | $39.7K | 0.00% |
| XTX Topco Ltd | 12,492 | $27.1K | 0.00% |
| Rockefeller Capital Management L.P. | 83 | $180 | 0.00% |
| Citigroup Inc | 49 | $106 | 0.00% |
Sold out (1)
Institutions that held IN8BIO, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| AIGH Capital Management LLC | 149,895 | $313.3K |